chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Information has been received from a licensed practical nurse concerning a 15 month old female pt with a history of erythema multiforme following exposure to varicella virus vaccine live (MSD) (WAES 00072512) who was vaccinated with a 1st dose of MMRII SC in the left leg. That same day the pt also had a 4th dose of Haemophilus B conjugate vaccine IM in the left leg. On 7/26/00, the pt developed erythema multiforme. Unspecified medical attention was sought and the pt's experience was thought to be an allergy and treated at the time of the occurrence. Follow-up information from a physician indicated that "10 days, post vax, the pt developed red target lesions and urticarial rash (had a similar reaction to the varicella virus vaccine before". On 7/30/00, the pt recovered.
Weakness, aches (head, muscles, joints), fever/chills, nausea - treated with 440 mg naproxen plus 1000 mg acetaminophen which took the edge off but still symptomatic.
swelling; Initial information received on 22-Jan-2021 regarding an unsolicited valid non-serious case received from a physician.  This case involves adult patient of unknown demographics who experienced swelling, while the patient received INFLUENZA USP TRIVAL A-B HIGH DOSE SUBVIRION VACCINE [FLUZONE HIGH DOSE].  The patient's medical history, past medical treatment(s), vaccination(s) and family history were not provided. Concomitant medication was not reported.  On an unknown date, the patient received a dose of suspect INFLUENZA USP TRIVAL A-B HIGH DOSE SUBVIRION VACCINE (lot number and expiration date were not reported) via unknown route in unknown administration site for prophylactic vaccination.  On an unknown date, the patient developed a non-serious swelling following the administration of INFLUENZA USP TRIVAL A-B HIGH DOSE SUBVIRION VACCINE.  No laboratory test was reported.   It was not reported if the patient received a corrective treatment.  The patient was reported as unknown.
On 7/31 I noticed two bright red spots on my upper thigh.On 8/1 I noticed about a dozen bright red spots some with white raised pimply spots in the middle. They looked just like pictures of chicken pox and if memory serves like the ones my kids had
Vaccine given at 8am on 1/5/21. The same afternoon, burning feeling in chest and head, flushed feeling, slight chest tightness and headache started. The symptoms have been returning daily since then. No fever, blood pressure, SpO2 and heart rate in the normal range.
Patient reports a rash around injection site and tenderness to the touch. Originally was swollen and red, but has since improved. Patient still notes a small discoloration around injection site measuring approximately 2". Patient reports this 8 days post vaccination.
Heart palpitations the night of the vaccine shot. Chest tightness for 10 after the shot. I contacted my PCP and she had me come in for assessment. Did and ecg and determined that right now, it was normal. Said that I should track my palpitations and tightness and would give me a cardio referral if I wanted.  On 4/30 had chest discomfort and a bubble feeling in my throat so I went into urgent care. Did another ecg and found a sinus arrhythmia.
Rash; This is a spontaneous report from a contactable consumer (patient). This 88-year-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE) on 28May2021, at the age of 88 years, as the second single dose, for COVID-19 immunization. No other vaccine was administered in four weeks. Medical history included penicillin allergy, sulfa allergy and COVID-19 prior vaccination. The patient was not pregnant. The patient received the first dose of BNT162B2 vaccine 06May2021 at 10:00 AM, experiencing rash and itching 10 days after vaccination. Concomitant medications were not reported. The patient received the second dose of vaccine on 28May2021. Rash was still on body after 4 months. COVID was not tested after vaccination. Rash had not yet resolved.  The lot number for BNT162b2 was not provided and will be requested during follow up.; Sender's Comments: Linked Report(s) : US-PFIZER INC-202101206952 same pt/drug, event from diff dose
I95.9 HYPOTENSION 8/13/2022 CANCER METASTATIC TO UNSPECIFIED LN I95.9 HYPOTENSION 8/13/2022 CANCER METASTATIC TO UNSPECIFIED LN I95.9 HYPOTENSION 8/13/2022 ABDOMINAL PAIN
No adverse event; Third dose administered 0.3ml; This spontaneous case was reported by an other health care professional and describes the occurrence of ACCIDENTAL OVERDOSE (Third dose administered 0.3ml) and NO ADVERSE EVENT (No adverse event) in a 77-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 301458A) for COVID-19 prophylaxis.     Patient had ever been diagnosed or tested positive for COVID-19 was unknown. Acute illness at the time of vaccination and up to one month prior was reported as unknown. Chronic and long standing health condition was reported as unknown.    On 30-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 20-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 07-Oct-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to .3 milliliter. On 07-Oct-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced ACCIDENTAL OVERDOSE (Third dose administered 0.3ml). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, ACCIDENTAL OVERDOSE (Third dose administered 0.3ml) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for ACCIDENTAL OVERDOSE (Third dose administered 0.3ml).    No concomitant medication information was provided. No treatment medication information was provided.   This case was linked to MOD-2022-620475, MOD-2022-608998 (Patient Link).
Immunized patient and told him  to wait 15 minutes before leaving. Everything went well in the vaccination room. We were talking and he was fine. He went to the waiting room and all of a sudden he told his wife he thought he was going to faint. He did and she got on his lap immediately so he wouldn't fall. She was tapping his face and talking to him. Others in the waiting room were helping. He punched his wife in the stomach (she is pregnant) but she seemed to be ok as she was trying to get him back to normal. I called 911 and  manager gave him water and ice. The paramedics came and checked him out to make sure he was ok. He was very alert by the time they got here and then they left. He continued to sit for awhile and I asked if his wife would be driving. She said yes. I told him if they needed anything to call us.d
Spoke to mom, seizure 11/25/09, temp. 102.5. To ER and transferred to hospital 11/26/09 and discharged Sunday 11/29/09. Has not returned to school yet. Season flu shot received 11/17/09.
Per patient, she started to have generalized weakness and myalgias after flu vaccine on 10/21/2010, no fevers or chills. Also with difficulty sleeping and exhaustion/ fatigue. Seen for first visit 11/10/2010 for follow up with persistent myalgias and feeling of weakness and dizziness, vitals normal. At that visit, had ESR sent, mildly high, with normal CPK/ CBC except for mild eosinophilia/ CMP. Started on naproxen BID with resolution of symptoms at follow up 11/17/2010 but still with mildly elevated ESR to 40, CBC with mild anemia.
Coughing; Throwing up; Complaining about her breathing; This is a spontaneous report from a contactable consumer or other non hcp.    A 95-years-old female patient received bnt162b2 (BNT162B2 PFIZER BIOTECH COVID 19 MRNA VACCINE SOLUTION FOR INJECTION), dose 3 via an unspecified route of administration on an immunisation. Medical history included dyspnoea. Patient has had breathing problems before and has been on breathing medicine. The patient's concomitant medications were not reported. It was reported that, the patient experienced coughing, throwing up, complaining about her breathing on an unspecified date with outcome of unknown. Therapeutic measures were taken as a result of coughing (cough), throwing up (vomiting), complaining about her breathing (dyspnoea). Patient has been taking plenty of fluids and drinking Gatorade.   The lot number for the vaccine, [BNT162B2], was not provided and will be requested during follow up.
This case was reported by a consumer via call center representative and described the occurrence of fever in a 92-year-old female patient who received SHINGRIX for prophylaxis. On 10th July 2018, the patient received the 2nd dose of SHINGRIX (intramuscular). On 10th July 2018, less than a day after receiving SHINGRIX, the patient experienced fever, pain, influenza-like symptoms, feeling cold, headache, shivering and feeling abnormal. In July 2018, the patient experienced weakness. On an unknown date, the outcome of the fever, pain, influenza-like symptoms, feeling cold and shivering were recovering/resolving and the outcome of the weakness was not recovered/not resolved and the outcome of the headache was recovered/resolved and the outcome of the feeling abnormal was unknown. It was unknown if the reporter considered the fever, pain, influenza-like symptoms, feeling cold, weakness, headache, shivering and feeling abnormal to be related to SHINGRIX. Additional details were received as follows: The patient received SHINGRIX on the left arm and experienced fever, headache and felt terrible like had a bad flu with shivering and feeling cold and a bit weak. The patient didn't felt like herself in the next morning due to being weak. The patient reported that most of her symptoms started last evening after receiving the vaccine around 2:00 PM except weakness which occurred the morning of the reporting date. The patient had denied permission to contact their physician.
t103, irritability, lethargy, apathy, dec PO severe x 48hrs p/vax lasted 1 2k p/vax w/o other signs of illness or hx antecedent illness
Within 5-15 mins after getting vaccine patients face started to swell and she began itching and broke out in hive on face, neck,  and trunk, some on arms/legs
This spontaneous report as received from a nurse refers to a 12 year old patient of unknown gender. The patient's relevant medical history, concurrent conditions, concomitant medications, drug reactions or allergies were not reported. On 30-AUG-2017, the patient was vaccinated with improperly stored GARDASIL 9 (dosing details were not reported) (lot # N007931, expiry date: 17-NOV-2019) for prophylaxis. No adverse effects were reported. Temperature excursion was from 0 degree Celsius (C) to 1 degree C (0.8 degree C) for 52 minutes. The previous temperature excursion was reported as from 9 degree C to 25 degree C (10.9 degree C) for 3 hours 17 minutes. The call was because of a data logger. No product quality complaint involved. This is one of several reports received from the same reporter. Sender's Comments: US-009507513-1709USA000054.
Severe muscle pain radiating from injection site outward to all of upper left arm, headache at front of head, fatigue
15NOV91 sx runny nose, t101 R; 22NOV91 dx by MD BOM & sore throat ATB started; 23NOV91 dec appetite x 3 days, t101 R, rash upper chest; 24NOV91 admitted to hosp dx w/dehydration & reaction to MMR; IV fluids given;
Rapid onset of shooting pain in lower back to limbs.  Fever chills, muscle pains for 6weeks, Difficulty ambulating, lethargy
11:33 Patient arrived to the observation area with nurse at side. Nurse observed upper body twitching and stated that patient voided in the chair.  Patient looks dazed and pale and requests to lie down.  Patient placed on stretcher with head down and feet up. Initials vitals taken. HR 38. Call was placed to EMS.  Patient states that she felt anxious while waiting and has a history of panic attacks.    11:40 Patient appearance has improved.  2nd set of vitals taken show improvement.  Patient states that she feels better and placed a call to her daughter. Awaiting EMS arrival.  11:45 Patient transported via EMS to ED for further treatment and follow up.  15:00 Follow up call placed to ED.  Patient stable and may be admitted for further observation
Information has been received from a registered nurse concerning a female (age unknown), with unknown medical history and unknown drug reactions/allergies reported, who on 27-DEC-2005 was vaccinated intramuscularly with a 0.5 ml dose of pneumococcal 23v polysaccharide vaccine (650457/0937P).  On 27-DEC-2005 the patient experienced a sore achy arm which was red and hot to touch with swelling to the elbow.  Subsequently, on "about" 30-DEC-2005, the symptoms resolved and the patient recovered.  Unspecified medical attention was sought.  No product quality complaint was involved.  Additional information has been requested.
2 morning a red rash appeared and was present for 1 week. It itch and was sore.
Expired Product Used; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of expired vaccine used in a 46-year-old male patient who received DTPa (Reduced antigen) (Boostrix) (batch number HF2YA, expiry date 15-JUL-2023) for prophylaxis.   On 01-AUG-2023, the patient received Boostrix. On 01-AUG-2023, an unknown time after receiving Boostrix, the patient experienced expired vaccine used (Verbatim: Expired Product Used). The outcome of the expired vaccine used was unknown.   Additional Information: GSK Receipt Date: 02-AUG-2023 At the time of reporting, the dose had not been repeated. The vaccine administration facility was the same as primary reporter. The reporter consented to follow up.  The patient received an expired dose of Boostrix, which led to expired vaccine used.
PATIENT CLAIMED TO HAVE DIZZINESS, BLURRED VISION, UNCOMFORTABLE TO WALK AND ANXIETY AFTER SHOT.
area was hot, a bit swollen, and angry.; Red from above the site of the injection site to all the way down to the elbow; Part of the area was raised and about the size of half a baseball.; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE WARMTH (area was hot, a bit swollen, and angry.), VACCINATION SITE ERYTHEMA (Red from above the site of the injection site to all the way down to the elbow) and VACCINATION SITE SWELLING (Part of the area was raised and about the size of half a baseball.) in a 77-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 027l20a) for COVID-19 vaccination.     No Medical History information was reported.    On 15-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 23-Jan-2021, the patient experienced VACCINATION SITE ERYTHEMA (Red from above the site of the injection site to all the way down to the elbow) and VACCINATION SITE SWELLING (Part of the area was raised and about the size of half a baseball.). On an unknown date, the patient experienced VACCINATION SITE WARMTH (area was hot, a bit swollen, and angry.). The patient was treated with DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE]) (oral) at an unspecified dose and frequency. At the time of the report, VACCINATION SITE WARMTH (area was hot, a bit swollen, and angry.) was resolving and VACCINATION SITE ERYTHEMA (Red from above the site of the injection site to all the way down to the elbow) and VACCINATION SITE SWELLING (Part of the area was raised and about the size of half a baseball.) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Treatment details included Benadryl Spray, Steroid Cream, and Antibiotic.
eye problems / "like eyes are not in synch"/ "like one eye is sort of off"; Feeling sleepy; Itching at the injection site where the vaccinator placed latex band aid; Headaches, mainly over the right eye but is also over the left eye; Fever; On and off chilly feeling; Runny watering nose; This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of RHINORRHOEA (Runny watering nose), EYE DISORDER (eye problems / "like eyes are not in synch"/ "like one eye is sort of off"), SOMNOLENCE (Feeling sleepy), VACCINATION SITE PRURITUS (Itching at the injection site where the vaccinator placed latex band aid) and HEADACHE (Headaches, mainly over the right eye but is also over the left eye) in a 91-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Hypothyroidism, Runny nose (in winters), Latex allergy, Drug allergy (erythromycin and flecainide combination: developed atrial fibrillation) and Eyeglasses wearer (driving glass). Concomitant products included LEVOTHYROXINE, DULOXETINE HYDROCHLORIDE (CYMBALTA), VITAMIN C [ASCORBIC ACID], VITAMIN D NOS and TOCOPHEROL (VITAMIN E [TOCOPHEROL]) for an unknown indication.    On 27-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) .5 ml. On 27-Jan-2021, the patient experienced RHINORRHOEA (Runny watering nose), SOMNOLENCE (Feeling sleepy), VACCINATION SITE PRURITUS (Itching at the injection site where the vaccinator placed latex band aid), HEADACHE (Headaches, mainly over the right eye but is also over the left eye), PYREXIA (Fever) and CHILLS (On and off chilly feeling). On 02-Feb-2021, the patient experienced EYE DISORDER (eye problems / "like eyes are not in synch"/ "like one eye is sort of off"). The patient was treated with PARACETAMOL (TYLENOL) for Adverse event, at an unspecified dose and frequency and FEXOFENADINE HYDROCHLORIDE (ALLEGRA) for Adverse event, at an unspecified dose and frequency. On 03-Feb-2021, SOMNOLENCE (Feeling sleepy), VACCINATION SITE PRURITUS (Itching at the injection site where the vaccinator placed latex band aid), HEADACHE (Headaches, mainly over the right eye but is also over the left eye), PYREXIA (Fever) and CHILLS (On and off chilly feeling) had resolved. At the time of the report, RHINORRHOEA (Runny watering nose) outcome was unknown and EYE DISORDER (eye problems / "like eyes are not in synch"/ "like one eye is sort of off") had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.
PATIENT RECEIVED VACCINE THAT EXPERIENCED A TEMPERATURE EXCURSION, VACCINE WAS KEPT IN THE REFRIGERATOR FOR MORE THAN 30 DAYS. NO PROBLEMS.
This spontaneous report was received from a nurse (patient's mother), via company representative, regarding her daughter of 12 or 13 years old (currently she is 19 years old). The patient's medical history, concurrent conditions and concomitant medications were not reported. On an unknown dates, the patient was vaccinated with doses of GARDASIL intramuscular, (dosing details not provided). It was reported that the patient received all 3 doses of GARDASIL at the age of 12 or 13 years (exact age uncertain). The patient had unspecified adverse event on an unknown date while on therapy with GARDASIL. Then on unknown date, the patient was vaccinated with GARDASIL 9 as a fourth dose, (dose and route not provided) (Extra dose administered). Subsequently, on an unknown date, the patient experienced sore at injection site arm. The patient did not seek medical attention and no treatment was given to her. The outcome of the events was reported as recovered. Causality assessment was not provided. Additional information has been requested.
vaccine on Sat, 17th. Sunday developed mild injection site reaction., erythema and edema. Improving now. no systemic s/s
Information has been received from a female medical assistant who on an unspecified date was vaccinated with a dose of GARDASIL (lot number not reported). Subsequently on an unspecified date the patient's arm became swollen, red and hot for 3 days. It was unknown if medial attention was sought. At the time of the report, the patient had recovered. No further information is available.
This spontaneous report as received from a nurse refers to a patient of unknown age and gender. The patient's medical history and concurrent conditions were not reported. On 25-JUN-2013, the patient was vaccinated with GARDASIL (lot # J002641, expiry date: 10-DEC-2015) (route: intramuscular) at the age of 13 years old. Then on 05-JUL-2017, a dose of GARDASIL 9 (lot # N007931, expiry date: 17-NOV-2019) was administered when the patient was 17 years old (inappropriate schedule of drug administration). No adverse effects reported. The outcome of the events was unknown. The causality of the events was unknown. Additional information has been requested.
PATIENT PRESENTED TO HER DOCTOR (AND SUBSEQUENTLY) PHARMACY WITH REDNESS, SEVERE SWELLING, AND PAIN OF HER LEFT ARM TWO DAYS AFTER PNEUMONIA VACCINE. HER HUSBAND, WHO HAD THE SAME VACCINE, WAS EXPERIENCING THE SAME SYMPTOMS. DOCTOR DIAGNOSED AS CELLULITIS AND PRESCRIBED KEFLEX 500MG TID FOR 10 DAYS.
first dose / on 12-Aug-2019 / has not received dose two; This case was reported by a pharmacist via call center representative and described the occurrence of incomplete course of vaccination in a 78-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (1st dose received 12th August 2019).   On an unknown date, the patient received the 2nd dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced incomplete course of vaccination. On an unknown date, the outcome of the incomplete course of vaccination was unknown.  Additional case details were reported as follows: The case was reported by the patient. Age at vaccination was not applicable for this report. The patient had not received 2nd dose of Shingrix till the time of reporting which led to incomplete course of vaccination. The reporter consented to follow up. The case had been linked with US2021153988 reported by same reporter.; Sender's Comments:  US-GLAXOSMITHKLINE-US2021153988:Same reporter
her arm was very very red to the elbow; itchy; warm; swollen; a hard lump at the injection site that lasted for 2 weeks; her skin started to peel; Her arm is a little bit discolored; This spontaneous case was reported by a consumer and describes the occurrence of ERYTHEMA (her arm was very very red to the elbow), PRURITUS (itchy), SKIN WARM (warm), PERIPHERAL SWELLING (swollen) and INJECTION SITE MASS (a hard lump at the injection site that lasted for 2 weeks) in an 83-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 011A21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included No adverse event. Concomitant products included METFORMIN, LISINOPRIL, METOPROLOL, FOLIC ACID, LEVOTHYROXINE, SIMVASTATIN and FUROSEMIDE for an unknown indication.    On 26-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced ERYTHEMA (her arm was very very red to the elbow), PRURITUS (itchy), SKIN WARM (warm), PERIPHERAL SWELLING (swollen), INJECTION SITE MASS (a hard lump at the injection site that lasted for 2 weeks), SKIN EXFOLIATION (her skin started to peel) and SKIN DISCOLOURATION (Her arm is a little bit discolored). At the time of the report, ERYTHEMA (her arm was very very red to the elbow), PRURITUS (itchy), SKIN WARM (warm), PERIPHERAL SWELLING (swollen), INJECTION SITE MASS (a hard lump at the injection site that lasted for 2 weeks), SKIN EXFOLIATION (her skin started to peel) and SKIN DISCOLOURATION (Her arm is a little bit discolored) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       treatment includes Benadryl roll-on anti-itch